Monograph Details
|
|
Respiratory Tract
> Rhinitis/rhinorrhea (intranasal products)
|
|
BECONASE AQ |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid. |
| Generic Name |
|
Beclomethasone dipropionate 42micrograms/spray; aqueous nasal spray. |
| Indications |
|
Allergic and vasomotor rhinitis. Prophylaxis of nasal polyp recurrence. |
| Adults and Children |
|
<6 yrs: not recommended. ≥6 yrs: 1–2 sprays in each nostril twice daily. |
| Precautions |
|
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. May use nasal decongestants if needed. Reevaluate if no improvement in 3 wks; nasal polyp prophylaxis may warrant longer treatment. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Nasal discomfort, sneezing, headache, nausea, epistaxis, rhinorrhea, hypercorticism, impaired wound healing, increased intraocular pressure, reduced growth velocity in children. |
| How Supplied |
|
Beconase AQ—25g (180 sprays) |
|
|
|
|
